News By Tag
News By Place
Follow on Google News
How Neurologists' Prescribe Multiple Sclerosis Drugs to the Target MS Patient
By: Vivisum Partners, LLC
Across all available multiple sclerosis therapies, healthcare providers (HCPs) stratify patients primarily between mild to moderate and moderate to severe disease. Low or high disease activity MS patients are never the primary patient type for certain brands, such as Tecfidera, Aubagio and Mavenclad. According to Multiple Sclerosis Target Patient Analysis, Tecfidera continues to provide neurologists with a frequently used first-line DMT option to treat mild to moderate patients who are treatment-naï
For individuals who need to escalate their treatment, neurologists will look to a different group of therapies for these MS patients. Gilenya, for example, is a good intermediate option that provides a balance of efficacy, safety, and convenience for those patients who are mild to moderate and have failed 1 disease modifying therapy (DMT). Zeposia is also competing for this type of MS patient.
"Neurologists are split between using Gilenya for patients with mild to moderate activity vs. moderate to severe activity," said Ellen Hart, director and multiple sclerosis strategist at Vivisum Partners. "Patients with low activity or high activity are better suited for other products."
Multiple Sclerosis Target Patient Analysis, published in October 2022 by Vivisum Partners, breaks down common MS patient characteristics for 12 branded multiple sclerosis drugs and discusses how well each brand aligns with the following patient traits:
ABOUT VIVISUM PARTNERS, LLC
Vivisum Partners, LLC is a market research agency providing strategic consulting around marketing and brand building. Vivisum provides facilitated discovery using market research methodologies and critical thinking processes. The actionable market research insights that Vivisum provides enable clients to shape their commercial strategies.
Account Email Address Account Phone Number Disclaimer Report Abuse